Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilar Deals 2023
Diversity
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Litigation
Patents
PipCast®
PTE
Webinars

US Federal Court reverses CAR-T infringement decision

Aug 26, 2021

The US Federal Circuit reversed an infringement judgement against Kite Pharma (part of Gilead Pharma) of a patent relating to CAR-T therapies on the basis of lack of written description.  The Sloan Kettering Institute for Cancer Research owned patent at issue was licenced exclusively to Juno Therapeutics (now part of BMS).  Kite Pharma’s CAR-T therapy is Yescarta® (axicabtagene ciloleucel), which competes with Juno’s Breyanzo® (lisocabtagene maraleucel).

Print Page Mail Article